Table 3. Univariable analysis of clinico-pathological parameters for the prediction of cancer-specific survival in patients with colorectal cancer.
|
Cancer-specific survival
|
||
|---|---|---|
| Parameter | HR (95% CI) | P -value |
| Age at diagnosis (years) | ||
| <60 | 1 (Reference) | 0.526 |
| ⩾60 | 1.18 (0.71–1.95) | |
| Gender | ||
| Male | 1 (Reference) | 0.956 |
| Female | 1.02 (0.59–1.74) | |
| Tumour location | ||
| Colon | 1 (Reference) | 0.597 |
| Rectum | 0.87 (0.53–1.44) | |
| Tumour grade | ||
| G1+G2 | 1 (Reference) | <0.001 |
| G3 | 2.5 (1.41–4.4) | |
| Tumour stage | ||
| II+III | 1 (Reference) | 0.015 |
| IV | 1.9 (1.13–3.2) | |
| Lines of therapy | ||
| ⩽3 | 1 (Reference) | 0.052 |
| >3 | 0.59 (0.34–1.01) | |
| Level of CEA | ||
| Normal | 1 (Reference) | 0.003 |
| Increased | 2.25 (1.33–3.81) | |
| miRNA-143 expression | ||
| High | 1 (Reference) | 0.007 |
| Low | 2.09 (1.22–3.58) | |
Abbreviations: CEA=carcinoembryonic antigen; CI=confidence interval; HR=hazard ratio; miRNA=microRNA.